Ionis Announces Submission of New Drug Application (NDA) for Inotersen to the U.S. FDA

CARLSBAD, Calif., Nov. 6, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the company submitted a new drug application (NDA) to the U.S. Food and Drug Administration for inotersen, an investigational medicine for the treatment of patients with hereditary TTR amyloidosis (hATTR).

The release as fetched from its publisher. ionis.com ↗